Stockscreener 앱 받기
0.8041
2.07%
-0.017
시간 외 거래:
.80
-0.0041
-0.51%
전일 마감가:
$0.8211
열려 있는:
$0.83
하루 거래량:
1.25M
Relative Volume:
0.91
시가총액:
$153.54M
수익:
$4.71M
순이익/손실:
$-58.01M
주가수익비율:
-0.9766
EPS:
-0.8234
순현금흐름:
$-46.68M
1주 성능:
-15.46%
1개월 성능:
-16.34%
6개월 성능:
-42.97%
1년 성능:
-21.17%
1일 변동 폭
$0.7886
$0.8301
1주일 범위
$0.7886
$0.9587
52주 변동 폭
$0.7886
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
명칭
Lucid Diagnostics Inc
전화
212 949 4319
주소
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.8041 | 156.79M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 개시 | BTIG Research | Buy |
| 2021-11-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Needham | Buy |
Lucid Diagnostics Inc 주식(LUCD)의 최신 뉴스
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9.5 - Moomoo
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - AOL.com
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Sahm
LUCD Q1 2026 Earnings: EPS Misses by 100.7% as Commercialization Costs MountROIC Trend Report - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93SMA Signal - dars.gov.et
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage - scanx.trade
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript - Benzinga
LUCD: Revenue up 17% with stable cash, first LBM coverage, and Medicare LCD decision expected soon - TradingView
Transcript : Lucid Diagnostics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Earnings call transcript: Lucid Diagnostics posts Q2 2026 revenue beat, shares slip - Investing.com
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Form 8K Lucid Diagnostics Inc For: 13 August By Investing.com - Investing.com South Africa
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision - TipRanks
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (LUCD) Stock Slips As Lofty P S Meets Heavy Losses - webull.com
Lucid Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue - Quiver Quantitative
Lucid Diagnostics 2026: Revenue $1.47M, EPS ($0.08) — 10-Q Summary - TradingView
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside - Yahoo Finance
Lucid Diagnostics at canaccord growth conference: reimbursement push builds By Investing.com - Investing.com Australia
Lucid Diagnostics Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Enterprise value to EBIT forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - tradingview.com
Price to sales forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to book forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to earnings forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Lucid Diagnostics Inc (LUCD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.29%
0.75%
자본화:
|
볼륨(24시간):